About: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
Creator	Wang, Yuan Zhang, Liang Wang, Yang Zhang, Hui Cheng, Linfeng Zhang, Fanglin Ye, Wei Wang, Dan Liu, He Touret, Franck Ma, Hongwei Lei, Yingfeng Ye, Chuantao Xu, Zhikai Yao, Min Lv, Xin Marjomäki, Varpu Lei, Xu Dong, Yangchao Qi, Libin Yang, Yuewu Dutartre, Helene
Source	Medline; PMC
abstract	Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense Coronaviridae and Flaviviridae and negative-sense Filoviridae, Paramyxoviridae, and Pneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.3389/fmicb.2020.01105
bibo:pmid	32595613
has license	cc-by
sha1sum (hex)	8085a501313ae63c535650a4325f6d7443cdfc4e
schema:url	https://doi.org/10.3389/fmicb.2020.01105
resource representing a document's title	Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
has PubMed Central identifier	PMC7304253
has PubMed identifier	32595613
schema:publication	Front Microbiol
resource representing a document's body	covid:8085a501313ae63c535650a4325f6d7443cdfc4e#body_text
is schema:about of	named entity 'FAMILIES' named entity 'FORM' named entity 'NEGATIVE' named entity 'HUMAN' named entity 'DISEASE' named entity 'NOVEL' named entity 'THERAPY' named entity 'antivirals' named entity 'EV71' named entity 'enterovirus infections' named entity 'antiviral activity' named entity 'negative-sense' named entity 'therapeutic agent' named entity 'clinical therapy' named entity 'enteroviruses' named entity 'vRNA' named entity 'Coronaviridae' named entity 'enterovirus' named entity 'enteroviruses' named entity 'Flaviviridae' named entity 'Pneumoviridae' named entity 'GS-5734' named entity 'Enterovirus' named entity 'Remdesivir' named entity 'remdesivir' named entity 'mouse model' named entity 'remdesivir' named entity '0.01' named entity 'remdesivir' named entity 'phosphoramidate' named entity 'antibody' named entity 'China' named entity 'Phylogenetic analyses' named entity 'primers' named entity 'remdesivir' named entity 'EV71' named entity 'EV71' named entity 'virus replication' named entity 'La Jolla' named entity 'United States' named entity 'remdesivir' named entity 'efficacies' named entity 'remdesivir' named entity 'P-selectin glycoprotein ligand-1' named entity 'Sigma-Aldrich' named entity 'Hungary' named entity 'human parainfluenza virus' named entity 'China' named entity 'Ebola' named entity 'China' named entity 'noroviruses' named entity 'Immunofluorescence assays' named entity 'Shanghai' named entity 'respiratory syncytial virus' named entity 'viruses' named entity 'United States' named entity 'virions' named entity 'EV71' named entity 'supportive therapy' named entity 'RNase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software